# US 2019/0169635 A1 · Mouse Model of Alpha-One Antitrypsin (AAT) Deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169635 A1
- Document ID: US20190169635A1
- Status: Published application
- Kind: A1
- Application number: 16/216,324
- Filed: 2018-12-11
- Published: 2019-06-06
- Earliest claimed: 2016-05-13
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Christian Mueller; Florie Borel
- Web page: https://patentgrep.com/patent/US20190169635A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0276: Knock-out vertebrates
- C07K 14/8125: {Alpha-1-antitrypsin}
- C12N 15/09: Recombinant DNA-technology
- A01K 2227/105: Murine
- A01K 2267/0306: Animal model for genetic diseases
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 2015/8527: {for producing animal models, e.g. for tests or diseases}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Transgenic non-human animals, e.g., rodents, e.g., mice comprising genomic mutations that inactive all of the serpin1A genes and thus lack any functional serpinA1 genes. As a result of the genomic mutations, the animals express no hepatic or circulatory AAT protein. Also provided herein are cells and tissues derived from the transgenic mice.

## Claims

### Claim 1

A method of evaluating an effect of a test compound on development of Alpha-One Antitrypsin (AAT)-deficiency lung disease, the method comprising:
providing a transgenic mouse whose genome comprises inactivating mutations in exon 2 of each of Serpina1a, Serpina1b, Serpina1c, Serpina1d, and Serpina1e genes, and which expresses no hepatic or circulatory AAT protein;
exposing the mouse to the test compound; and
evaluating a parameter of respiratory physiology in the transgenic mouse.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inactivating mutations comprise deletions in exon 2.

### Claim 3 (depends on 1)

The method of claim 1, wherein the transgenic mouse is a mouse model of Alpha-One Antitrypsin (AAT)-deficiency lung disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the test compound is an environmental factor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the environmental factor is a toxin.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mouse is exposed to untested air particulates or vaping.

### Claim 7 (depends on 1)

The method of claim 1, comprising measuring the parameter in the animal before exposure, and during and/or after exposure to the test compound.

### Claim 8 (depends on 1)

The method of claim 1, wherein the parameter of respiratory physiology is respiratory volume, inspiratory capacity, elastance, compliance, and/or quasi-static compliance.

### Claim 9 (depends on 1)

The method of claim 1, further comprising:
exposing the mouse to a potential therapeutic; and
evaluating a parameter of respiratory physiology in the transgenic mouse.

### Claim 10 (depends on 9)

The method of claim 9, comprising exposing the mouse to a potential therapeutic before, during and/or after exposing the mouse to the test compound.

### Claim 11

A method of evaluating an effect of a test compound on development of Alpha-One Antitrypsin (AAT)-deficiency lung disease, the method comprising:
providing a cell, tissue, or organ from a transgenic mouse whose genome comprises inactivating mutations in exon 2 of each of Serpina1a, Serpina1b, Serpina1c, Serpina1d, and Serpina1e genes, and which expresses no hepatic or circulatory AAT protein;
exposing the cell, tissue, or organ to the test compound; and
evaluating a level of elastase in the cell, tissue, or organ.

### Claim 12 (depends on 11)

The method of claim 11, wherein the inactivating mutations comprise deletions in exon 2.

### Claim 13 (depends on 11)

The method of claim 11, wherein the transgenic mouse is a mouse model of Alpha-One Antitrypsin (AAT)-deficiency lung disease.

### Claim 14 (depends on 11)

The method of claim 11, wherein the test compound is an environmental factor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the environmental factor is a toxin.

### Claim 16 (depends on 11)

The method of claim 11, wherein the cell, tissue, or organ is exposed to untested air particulates or vaping.

### Claim 17 (depends on 11)

The method of claim 11, comprising measuring elastase in the cell, tissue, or organ before exposure, and during and/or after exposure to the test compound.

### Claim 18 (depends on 11)

The method of claim 11, further comprising:
exposing the cell, tissue, or organ to a potential therapeutic; and
evaluating a level of elastase in the cell, tissue, or organ.

### Claim 19 (depends on 19)

The method of claim 19, comprising exposing the cell, tissue, or organ to a potential therapeutic before, during and/or after exposing the cell, tissue, or organ to the test compound.
